Immunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS

Reuters

2025/06/05

Immunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS

Immunic, Inc., a biotechnology company specializing in treatments for chronic inflammatory and autoimmune diseases, has completed enrollment for its phase 3 ENSURE trials for vidofludimus calcium in patients with relapsing multiple sclerosis $(RMS.AU)$. Involving over 2,200 participants, these trials represent a significant milestone toward potential regulatory approval and commercialization. The company expects top-line data by the end of 2026. Additionally, new data from the phase 2 CALLIPER trial in progressive multiple sclerosis (PMS) highlights the neuroprotective potential of vidofludimus calcium, showing substantial reductions in time to 24-week confirmed disability worsening compared to a placebo. Dr. Daniel Vitt, CEO of Immunic, emphasized the drug's promising safety profile and its potential to transform the oral MS therapy market by offering a novel treatment option with neuroprotective, anti-inflammatory, and antiviral effects.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY03900) on June 05, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2541021720"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541021720\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2541021720?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-05 18:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541021720","market":"nz","top_or_hot":-1,"title":"Immunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IMUX\">Immunic, Inc.</a>, a biotechnology company specializing in treatments for chronic inflammatory and autoimmune diseases, has completed enrollment for its phase 3 ENSURE trials for vidofludimus calcium in patients with relapsing multiple sclerosis <a href=\"https://laohu8.com/S/RMS.AU\">$(RMS.AU)$</a>. Involving over 2,200 participants, these trials represent a significant milestone toward potential regulatory approval and commercialization. The company expects top-line data by the end of 2026. Additionally, new data from the phase 2 CALLIPER trial in progressive multiple sclerosis (PMS) highlights the neuroprotective potential of vidofludimus calcium, showing substantial reductions in time to 24-week confirmed disability worsening compared to a placebo. Dr. Daniel Vitt, CEO of Immunic, emphasized the drug's promising safety profile and its potential to transform the oral MS therapy market by offering a novel treatment option with neuroprotective, anti-inflammatory, and antiviral effects.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY03900) on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-05 18:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IMUX\">Immunic, Inc.</a>, a biotechnology company specializing in treatments for chronic inflammatory and autoimmune diseases, has completed enrollment for its phase 3 ENSURE trials for vidofludimus calcium in patients with relapsing multiple sclerosis <a href=\"https://laohu8.com/S/RMS.AU\">$(RMS.AU)$</a>. Involving over 2,200 participants, these trials represent a significant milestone toward potential regulatory approval and commercialization. The company expects top-line data by the end of 2026. Additionally, new data from the phase 2 CALLIPER trial in progressive multiple sclerosis (PMS) highlights the neuroprotective potential of vidofludimus calcium, showing substantial reductions in time to 24-week confirmed disability worsening compared to a placebo. Dr. Daniel Vitt, CEO of Immunic, emphasized the drug's promising safety profile and its potential to transform the oral MS therapy market by offering a novel treatment option with neuroprotective, anti-inflammatory, and antiviral effects.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY03900) on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL9J2cVq:1","article_id":"2541021720","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541021720","pubTimestamp":1749119431,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Immunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via PR Newswire  on June 05, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IMUX":"Immunic, Inc."},"translate_title":"Immunic Inc.宣布完成复发性MS 3期试验的招募，并强调进行性MS 2期试验的积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMUX":0.9},"content_text":"Immunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS\n    \n\nImmunic, Inc., a biotechnology company specializing in treatments for chronic inflammatory and autoimmune diseases, has completed enrollment for its phase 3 ENSURE trials for vidofludimus calcium in patients with relapsing multiple sclerosis $(RMS.AU)$. Involving over 2,200 participants, these trials represent a significant milestone toward potential regulatory approval and commercialization. The company expects top-line data by the end of 2026. Additionally, new data from the phase 2 CALLIPER trial in progressive multiple sclerosis (PMS) highlights the neuroprotective potential of vidofludimus calcium, showing substantial reductions in time to 24-week confirmed disability worsening compared to a placebo. Dr. Daniel Vitt, CEO of Immunic, emphasized the drug's promising safety profile and its potential to transform the oral MS therapy market by offering a novel treatment option with neuroprotective, anti-inflammatory, and antiviral effects.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY03900) on June 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}